390 related articles for article (PubMed ID: 26408162)
1. Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis.
Pryce G; Baker D
Handb Exp Pharmacol; 2015; 231():213-31. PubMed ID: 26408162
[TBL] [Abstract][Full Text] [Related]
2. Potential control of multiple sclerosis by cannabis and the endocannabinoid system.
Pryce G; Baker D
CNS Neurol Disord Drug Targets; 2012 Aug; 11(5):624-41. PubMed ID: 22583441
[TBL] [Abstract][Full Text] [Related]
3. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.
Shoemaker JL; Seely KA; Reed RL; Crow JP; Prather PL
J Neurochem; 2007 Apr; 101(1):87-98. PubMed ID: 17241118
[TBL] [Abstract][Full Text] [Related]
4. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide.
Loría F; Petrosino S; Mestre L; Spagnolo A; Correa F; Hernangómez M; Guaza C; Di Marzo V; Docagne F
Eur J Neurosci; 2008 Aug; 28(4):633-41. PubMed ID: 18657182
[TBL] [Abstract][Full Text] [Related]
5. The endocannabinoid system and multiple sclerosis.
Baker D; Pryce G
Curr Pharm Des; 2008; 14(23):2326-36. PubMed ID: 18781983
[TBL] [Abstract][Full Text] [Related]
6. The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis.
Rossi S; Bernardi G; Centonze D
Exp Neurol; 2010 Jul; 224(1):92-102. PubMed ID: 20353778
[TBL] [Abstract][Full Text] [Related]
7. Distribution of the Endocannabinoid System in the Central Nervous System.
Hu SS; Mackie K
Handb Exp Pharmacol; 2015; 231():59-93. PubMed ID: 26408158
[TBL] [Abstract][Full Text] [Related]
8. Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders.
Espejo-Porras F; Piscitelli F; Verde R; Ramos JA; Di Marzo V; de Lago E; Fernández-Ruiz J
J Neuroimmune Pharmacol; 2015 Jun; 10(2):233-44. PubMed ID: 25819934
[TBL] [Abstract][Full Text] [Related]
9. The endocannabinoid system in amyotrophic lateral sclerosis.
Bilsland LG; Greensmith L
Curr Pharm Des; 2008; 14(23):2306-16. PubMed ID: 18781981
[TBL] [Abstract][Full Text] [Related]
10. Targeting the CB
Rodríguez-Cueto C; García-Toscano L; Santos-García I; Gómez-Almería M; Gonzalo-Consuegra C; Espejo-Porras F; Fernández-Ruiz J; de Lago E
Br J Pharmacol; 2021 Mar; 178(6):1373-1387. PubMed ID: 33486755
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoids and the expanded endocannabinoid system in neurological disorders.
Cristino L; Bisogno T; Di Marzo V
Nat Rev Neurol; 2020 Jan; 16(1):9-29. PubMed ID: 31831863
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of cannabinoid receptor ligands: current status.
Singh J; Budhiraja S
Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):177-83. PubMed ID: 16810344
[TBL] [Abstract][Full Text] [Related]
13. The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases.
Chiurchiù V; van der Stelt M; Centonze D; Maccarrone M
Prog Neurobiol; 2018 Jan; 160():82-100. PubMed ID: 29097192
[TBL] [Abstract][Full Text] [Related]
14. An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis.
Loría F; Petrosino S; Hernangómez M; Mestre L; Spagnolo A; Correa F; Di Marzo V; Docagne F; Guaza C
Neurobiol Dis; 2010 Jan; 37(1):166-76. PubMed ID: 19815071
[TBL] [Abstract][Full Text] [Related]
15. The cannabinoid system and microglia in health and disease.
Duffy SS; Hayes JP; Fiore NT; Moalem-Taylor G
Neuropharmacology; 2021 Jun; 190():108555. PubMed ID: 33845074
[TBL] [Abstract][Full Text] [Related]
16. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
[TBL] [Abstract][Full Text] [Related]
17. The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis.
Centonze D; Rossi S; Finazzi-Agrò A; Bernardi G; Maccarrone M
Int Rev Neurobiol; 2007; 82():171-86. PubMed ID: 17678961
[TBL] [Abstract][Full Text] [Related]
18. Gut feelings about the endocannabinoid system.
Di Marzo V; Piscitelli F
Neurogastroenterol Motil; 2011 May; 23(5):391-8. PubMed ID: 21481098
[TBL] [Abstract][Full Text] [Related]
19. The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.
Baker D; Pryce G; Jackson SJ; Bolton C; Giovannoni G
Mult Scler Relat Disord; 2012 Apr; 1(2):64-75. PubMed ID: 25876933
[TBL] [Abstract][Full Text] [Related]
20. Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction.
Di Marzo V
Expert Rev Neurother; 2011 Apr; 11(4 Suppl):9-14. PubMed ID: 21449854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
